Table S3 from Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study

Autor: Antoni Ribas, Toni K. Choueiri, Rodolfo F. Perini, Blanca Homet Moreno, Xinxin Shu, Seth Robey, Lokesh Jain, Marihella James, Shailender Bhatia, Deborah J. Wong, Nancy A. Dawson, Donald P. Lawrence, Wen-Jen Hwu, David F. McDermott, John A. Thompson, F. Stephen Hodi, Michael B. Atkins
Rok vydání: 2023
DOI: 10.1158/1078-0432.22469943
Popis: Treatment-Related Adverse Events Occurring in {greater than or equal to}1 Patient Treated With Pembrolizumab plus Ipilimumab
Databáze: OpenAIRE